You are here: Home » Companies » News
Business Standard

Teva exec's remark creates furore in Indian pharma

Joe C Mathew  |  New Delhi 

Domestic drugmakers — used to frequent India bashing by research-driven global pharmaceutical majors for alleged infringement of patent rights or quality issues — were in for a shock last week when the world’s largest generic company, Israel’s Teva, made allegations against the industry practices in India and China.

Teva Europe’s President and CEO, Gerald Van Odijk, said the analyses of prices of Indian and Chinese drug showed they were cutting corners and wanted European drug regulator’s to conduct dawn raids on facilities in these countries.

London-based pharma journal Scrip on June 10 reported that Odijk made these observations while participating in the annual meeting of the European Association of Pharmaceutical Full-line Wholesalers (GIRP) in Cannes.

Scrip reported that Odijk, citing recalls, asserted generic pricing had taken its toll on quality and stated Teva did not have presence in India or China as “you would never sit on a plane if you thought that the parts were coming from a dodgy factory somewhere that you didn’t know. So, why do we accept this for medicines?” Contradicting his company was not present in India, industry officials said it did outsource lot of material from the country.

“Teva has a significant presence in India. It acquired Regent Drugs in 2003 from the JK Group. Substantial investment has gone into the active pharmaceutical ingredient (API) or raw material facility, including the setting up of an research and development facility that was inaugurated in December 2005,” D G Shah, secretary general of the domestic drug industry lobby group Indian Pharmaceutical Alliance (IPA), said.

In 2008, Teva had acquired over 100 acres of land near Gwalior to build an API manufacturing facility. Teva had said that it considered India an interesting geographical region and was looking to broaden its activities in the country.

Industry officials said Teva was sourcing raw materials from several leading Indian companies, including Cipla, Dr Reddy’s and Glenmark and finished formulations from such as Emcure, Micro Labs and IPCA.

The alleged quality and pricing concerns expressed by Teva has not deterred any of the foreign multinational from sourcing raw materials and ready-to-use medicines from India.

Almost all foreign drugmakers, including GSK, Pfizer and Daiichi, have alliances and investments in India to source medicines for their global supplies.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, June 22 2010. 00:57 IST
RECOMMENDED FOR YOU
.